Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.

Coleman CM, Venkataraman T, Liu YV, Glenn GM, Smith GE, Flyer DC, Frieman MB.

Vaccine. 2017 Mar 14;35(12):1586-1589. doi: 10.1016/j.vaccine.2017.02.012. Epub 2017 Feb 23.

2.

Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.

Bengtsson KL, Song H, Stertman L, Liu Y, Flyer DC, Massare MJ, Xu RH, Zhou B, Lu H, Kwilas SA, Hahn TJ, Kpamegan E, Hooper J, Carrion R Jr, Glenn G, Smith G.

Vaccine. 2016 Apr 7;34(16):1927-35. doi: 10.1016/j.vaccine.2016.02.033. Epub 2016 Feb 24.

3.

An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization.

Raghunandan R, Lu H, Zhou B, Xabier MG, Massare MJ, Flyer DC, Fries LF, Smith GE, Glenn GM.

Vaccine. 2014 Nov 12;32(48):6485-92. doi: 10.1016/j.vaccine.2014.09.030. Epub 2014 Sep 28.

4.

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice.

Coleman CM, Liu YV, Mu H, Taylor JK, Massare M, Flyer DC, Smith GE, Frieman MB.

Vaccine. 2014 May 30;32(26):3169-3174. doi: 10.1016/j.vaccine.2014.04.016. Epub 2014 Apr 13.

5.

Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.

Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF 3rd, Glenn GM.

Vaccine. 2013 Sep 13;31(40):4305-13. doi: 10.1016/j.vaccine.2013.07.043. Epub 2013 Jul 26.

6.

A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.

Tian JH, Fuhrmann SR, Kluepfel-Stahl S, Carman RJ, Ellingsworth L, Flyer DC.

Vaccine. 2012 Jun 13;30(28):4249-58. doi: 10.1016/j.vaccine.2012.04.045. Epub 2012 Apr 23.

PMID:
22537987
7.

Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.

Glenn GM, Thomas DN, Poffenberger KL, Flyer DC, Ellingsworth LR, Andersen BH, Frech SA.

Vaccine. 2009 Dec 30;27 Suppl 6:G60-6. doi: 10.1016/j.vaccine.2009.10.031.

PMID:
20006142
8.

Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial.

Frech SA, Dupont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF, Okhuysen PC, Guerrero NH, Martinez-Sandoval FG, Meléndez-Romero JH, Jiang ZD, Asturias EJ, Halpern J, Torres OR, Hoffman AS, Villar CP, Kassem RN, Flyer DC, Andersen BH, Kazempour K, Breisch SA, Glenn GM.

Lancet. 2008 Jun 14;371(9629):2019-25. doi: 10.1016/S0140-6736(08)60839-9.

PMID:
18554712
9.

Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch.

Frerichs DM, Ellingsworth LR, Frech SA, Flyer DC, Villar CP, Yu J, Glenn GM.

Vaccine. 2008 May 23;26(22):2782-7. doi: 10.1016/j.vaccine.2008.02.070. Epub 2008 Mar 28.

PMID:
18455283
10.

Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch.

Glenn GM, Flyer DC, Ellingsworth LR, Frech SA, Frerichs DM, Seid RC, Yu J.

Expert Rev Vaccines. 2007 Oct;6(5):809-19. Review.

PMID:
17931160
11.

Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.

McKenzie R, Bourgeois AL, Frech SA, Flyer DC, Bloom A, Kazempour K, Glenn GM.

Vaccine. 2007 May 4;25(18):3684-91. Epub 2007 Jan 23.

PMID:
17313998
12.

Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum.

Glenn GM, Villar CP, Flyer DC, Bourgeois AL, McKenzie R, Lavker RM, Frech SA.

Infect Immun. 2007 May;75(5):2163-70. Epub 2007 Jan 29.

13.

Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells.

Ramakrishna V, Ross MM, Petersson M, Gatlin CC, Lyons CE, Miller CL, Myers HE, McDaniel M, Karns LR, Kiessling R, Parmiani G, Flyer DC.

Int Immunol. 2003 Jun;15(6):751-63.

PMID:
12750359
14.

Identification by mass spectrometry of CD8(+)-T-cell Mycobacterium tuberculosis epitopes within the Rv0341 gene product.

Flyer DC, Ramakrishna V, Miller C, Myers H, McDaniel M, Root K, Flournoy C, Engelhard VH, Canaday DH, Marto JA, Ross MM, Hunt DF, Shabanowitz J, White FM.

Infect Immun. 2002 Jun;70(6):2926-32.

15.

Glycosylphosphatidylinositol-anchored H-2Db molecules are defective in antigen processing and presentation to cytotoxic T lymphocytes.

Cariappa A, Flyer DC, Rollins CT, Roopenian DC, Flavell RA, Brown D, Waneck GL.

Eur J Immunol. 1996 Sep;26(9):2215-24.

PMID:
8814270
16.

Expression of the MuLV-tumor-associated antigen is restricted to MuLV-transformed cells.

Flyer DC, Sucheski B.

Int J Cancer. 1993 May 8;54(2):328-32.

PMID:
8387466
19.

Mechanism of induction of class I major histocompatibility antigen expression by murine leukemia virus.

Faller DV, Wilson LD, Flyer DC.

J Cell Biochem. 1988 Mar;36(3):297-309.

PMID:
3288646
23.

Expression and CTL recognition of cloned subgenomic fragments of Moloney murine leukemia virus in murine cells.

Flyer DC, Burakoff SJ, Faller DV.

Surv Immunol Res. 1985;4(2):168-72. No abstract available.

PMID:
3875887
25.

Cytotoxic T lymphocyte recognition of transfected cells expressing a cloned retroviral gene.

Flyer DC, Burakoff SJ, Faller DV.

Nature. 1983 Oct 27-Nov 2;305(5937):815-8.

PMID:
6605480
26.

Lyt phenotype of H-2b CTL effectors and precursors specific for the SV40 transplantation rejection antigen.

Flyer DC, Anderson RW, Tevethia SS.

J Immunol. 1982 Dec;129(6):2368-71.

PMID:
6292288
28.
30.

Demonstration of unique and common antigenic sites located on the SV40 large T and small t antigens.

Greenfield RS, Flyer DC, Tevethia SS.

Virology. 1980 Jul 30;104(2):312-22. No abstract available.

PMID:
6156542
31.

SV40 transplantation antigen: relationship to SV40-specific proteins.

Tevethia SS, Greenfield RS, Flyer DC, Tevethia MJ.

Cold Spring Harb Symp Quant Biol. 1980;44 Pt 1,:235-42. No abstract available.

PMID:
6253137

Supplemental Content

Loading ...
Support Center